Analyst Reco. Gilead Sciences, Inc.

Stocks

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-07-14 pm EDT			After hours 08:00:00 pm
130.04 ^USD	-1.04%		128.50	-1.18%

12:02am	African markets - factors to watch on July 15	RE
Jul. 14	Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo	RE

Analyst Reco.

Jul. 08	Morgan Stanley Adjusts Price Target Gilead Sciences to $166 From $168, Maintains Overweight Rating	MT
Jul. 07	Truist Securities Adjusts Gilead Sciences Price Target to $156 From $157	MT
Jul. 07	RBC Capital Adjusts Gilead Sciences Price Target to $120 From $122, Maintains Sector Perform Rating	MT
Jul. 06	HSBC Upgrades Gilead Sciences to Buy From Hold, Adjusts Price Target to $155 From $133	MT
Jun. 08	Gilead Sciences Faces Potential Threat From In Vivo CAR-T, RBC Says	MT
May. 20	Maxim Upgrades Gilead Sciences to Buy From Hold, Price Target is $165	MT
May. 19	Daiwa Securities Adjusts PT on Gilead Sciences to $150 From $161, Maintains Outperform Rating	MT
May. 11	Gilead's Emvistegrast Readout Unlikely to Move Stock, RBC Says	MT
May. 11	Rothschild & Co Redburn Adjusts Price Target on Gilead Sciences to $167 From $170	MT
May. 08	Leerink Partners Adjusts Price Target on Gilead Sciences to $146 From $148	MT
May. 08	Gilead Sciences' Increased Yeztugo Guidance is 'Good Enough' for the Stock, Morgan Stanley Says	MT
May. 08	Morgan Stanley Adjusts Price Target on Gilead Sciences to $168 From $175	MT
Apr. 28	Morgan Stanley Adjusts Gilead Sciences Price Target to $175 From $171, Maintains Overweight Rating	MT
Apr. 17	Goldman Sachs Adjusts Gilead Sciences Price Target to $130 From $125, Maintains Neutral Rating	MT
Apr. 17	Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $155 From $115, Maintains Overweight Rating	MT
Apr. 13	Citigroup Adjusts Gilead Sciences PT to $165 From $156, Maintains Buy Rating	MT
Apr. 10	Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $115 From $155, Maintains Overweight Rating	MT
Apr. 08	Gilead Sciences' Tubulis Buy Underscores Shift Beyond HIV, Oppenheimer Says	MT
Apr. 07	RBC Adjusts Price Target on Gilead Sciences to $123 From $118, Maintains Sector Perform Rating	MT
Mar. 31	Gilead Sciences Shows Solid Early Yeztugo Persistence but Limited Market Expansion, RBC Says	MT
Feb. 25	Daiwa Securities Adjusts Price Target on Gilead Sciences to $161 From $129, Maintains Outperform Rating	MT
Feb. 24	Gilead Sciences Acquiring Arcellx to Consolidate Anito-Cel Ownership, UBS Securities Says	MT
Feb. 20	Barclays Initiates Coverage on Gilead Sciences With Equal Weight Rating	MT
Feb. 19	Argus Adjusts Price Target on Gilead Sciences to $165 From $135, Maintains Buy Rating	MT
Feb. 18	Mizuho Securities Lifts Gilead Sciences Price Target to $170 From $140, Maintains Outperform Rating	MT